US Stocks Movement | Hims & Hers Health surges over 35% after hours, Novo Nordisk plans to sell its weight loss drug on the Hims platform

NightAirdropper · 2026-03-07T06:13:36+00:00

Hims & Hers Health stock surged over 35% after hours, as Novo Nordisk plans to collaborate with them to sell weight loss drugs, ending a legal dispute from last month. This new partnership is expected to be announced next Monday.

NightAirdropper

2026-03-07 06:13:36

Abstract generation in progress

Gelonghui March 7 | Hims & Hers Health (HIMS.US) surged over 35% after hours on the US stock market, with reports indicating that Novo Nordisk plans to sell its weight-loss drugs on the Hims & Hers Health Inc. platform, ending a highly publicized dispute between the two companies. The dispute escalated to legal action last month. An anonymous insider stated that Novo Nordisk and Hims may announce a new partnership as early as next Monday. The two companies previously reached a similar agreement last year, but after Hims refused to cease marketing and selling generic versions of the drugs, Novo Nordisk unilaterally terminated the agreement.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.